AKT1 and ovarian carcinoma: The derivatives were first tested for their ability to inhibit Akt activation in cell lines characterised by constitutive activation of the PI3K/Akt pathway and with a reported sensitivity to InsP5, namely ovarian cancer cells SKOV-3 and breast cancer cells SKBR3 (Piccolo et al, 2004; Maffucci et al, 2005).